Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Established Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014, 55099-55103 [2013-21797]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices
To submit
comments:
Send them to:
By mail .........
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
Under Section 7003(d) of the
Resource Conservation and Recovery
Act (‘‘RCRA’’), a commenter may
request an opportunity for a public
meeting in the affected area.
During the public comment period,
the Consent Decree may be examined
and downloaded at this Justice
Department Web site: https://
www.usdoj.gov/enrd/Consent_
Decrees.html. We will provide a paper
copy of the Consent Decree upon
written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ—ENRD, P.O. Box
7611, Washington, DC 20044–7611.
Please enclose a check or money order
for $22.25 (25 cents per page
reproduction cost) payable to the United
States Treasury. For a paper copy
without the appendices and signature
pages, the cost is $16.00.
Maureen M. Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2013–21850 Filed 9–6–13; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–378]
Established Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Established
Assessment of Annual Needs for the
List I Chemicals Ephedrine,
Pseudoephedrine, and
Phenylpropanolamine for 2014
Drug Enforcement
Administration (DEA), Department of
Justice.
ACTION: Notice.
AGENCY:
This notice establishes the
initial 2014 aggregate production quotas
for controlled substances in Schedules I
and II of the Controlled Substances Act
(CSA) and assessment of annual needs
for the List I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
DATES: Effective: September 9, 2013.
FOR FURTHER INFORMATION CONTACT:
Ruth A. Carter, Chief, Policy Evaluation
and Analysis Section, Office of
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:01 Sep 06, 2013
Jkt 229001
Diversion Control, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, VA 22152, Telephone: (202)
598–6812.
SUPPLEMENTARY INFORMATION:
Background
Section 306 of the CSA (21 U.S.C.
826) requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substance listed in Schedules I and II
and for the List I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine. This
responsibility has been delegated to the
Administrator of the DEA by 28 CFR
0.100. The Administrator, in turn, has
redelegated this function to the Deputy
Administrator, pursuant to 28 CFR
0.104.
The 2014 aggregate production quotas
and assessment of annual needs
represent those quantities of Schedules
I and II controlled substances and the
List I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine to be
manufactured in the United States in
2014 to provide for the estimated
medical, scientific, research, and
industrial needs of the United States,
lawful export requirements, and the
establishment and maintenance of
reserve stocks. These quotas include
imports of ephedrine, pseudoephedrine,
and phenylpropanolamine but do not
include imports of controlled
substances for use in industrial
processes.
On July 3, 2013, a notice titled,
‘‘Proposed Aggregate Production Quotas
for Schedule I and II Controlled
Substances and Proposed Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2014,’’ was
published in the Federal Register (78
FR 40186). That notice proposed the
2014 aggregate production quotas for
each basic class of controlled substance
listed in Schedules I and II and the 2014
assessment of annual needs for the List
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine. All interested
persons were invited to comment on or
object to the proposed aggregate
production quotas and the proposed
assessment of annual needs on or before
August 2, 2013.
Comments Received
DEA received seven comments from
DEA-registered manufacturers within
the published comment period on a
total of 23 Schedule I and II controlled
substances and one List I chemical.
Commenters stated that the proposed
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
55099
aggregate production quotas for (1Pentyl-1H-indol-3-yl)(2,2,3,3tetramethylcyclopropyl)methanone (UR144), [1-(5-fluoro-pentyl)-1H-indol-3yl](2,2,3,3tetramethylcyclopropyl)methanone
(XLR11), N-(1-adamantyl)-1-pentyl-1Hindazole-3-carboxamide (AKB48),
cathinone, amphetamine (for sale),
codeine (for conversion), codeine (for
sale), fentanyl, hydrocodone (for sale),
hydromorphone, levomethorphan,
methylphenidate, morphine (for
conversion), morphine (for sale),
noroxymorphone (for conversion),
oripavine, oxycodone (for sale),
oxymorphone (for conversion),
oxymorphone (for sale), phenylacetone,
tapentadol, tetrahydrocannabinol, and
thebaine were insufficient to provide for
the estimated medical, scientific,
research, and industrial needs of the
United States, export requirements, and
the establishment and maintenance of
reserve stocks. One commenter stated
that the proposed assessment of annual
needs quota for phenylpropanolamine
(for conversion) was insufficient to
provide for the estimated medical,
scientific, research, and industrial needs
of the United States, export
requirements, and the establishment
and maintenance of reserve stocks.
Determination of 2014 Aggregate
Production Quotas and Assessment of
Annual Needs
In determining the 2014 aggregate
production quotas and assessment of
annual needs, the DEA has taken into
consideration the above comments
along with the factors set forth at 21
CFR 1303.11 and 21 CFR 1315.11, in
accordance with 21 U.S.C. 826(a), and
other relevant factors, including the
consideration of 2013 manufacturing
quotas, current 2013 sales and
inventories, 2014 export requirements,
industrial use, additional applications
for quotas, as well as information on
research and product development
requirements. Based on this
information, the DEA has determined
that adjustments to the proposed
aggregate production quotas and
assessment of annual needs for 1-[1-(2Thienyl)cyclohexyl]piperidine,
carfentanil, cathinone,
dihydromorphine, dimethyltryptamine,
ecgonine, hydromorphone,
levomethorphan, lysergic acid
diethylamide, metazocine,
methamphetamine, dmethamphetamine (for conversion),
methyldesorphine, noroxymorphone
(for conversion), oxymorphone (for
conversion), phencyclidine,
phenylacetone, ephedrine (for
conversion), ephedrine (for sale),
E:\FR\FM\09SEN1.SGM
09SEN1
55100
Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices
phenylpropanolamine (for conversion),
and pseudoephedrine (for sale) are
warranted. This notice reflects those
adjustments.
Regarding (1-Pentyl-1H-indol-3yl)(2,2,3,3tetramethylcyclopropyl)methanone (UR144), [1-(5-fluoro-pentyl)-1H-indol-3yl](2,2,3,3tetramethylcyclopropyl)methanone
(XLR11), N-(1-adamantyl)-1-pentyl-1Hindazole-3-carboxamide (AKB48),
amphetamine (for sale), codeine (for
conversion), codeine (for sale), fentanyl,
hydrocodone (for sale),
methylphenidate, morphine (for
conversion), morphine (for sale),
oripavine, oxycodone (for sale),
oxymorphone (for sale), tapentadol,
tetrahydrocannabinol, thebaine, and
phenylpropanolamine (for sale), the
DEA has determined that the proposed
initial 2014 aggregate production quotas
and assessment of annual needs are
sufficient to meet the current 2014
estimated medical, scientific, research,
and industrial needs of the United
States. This notice finalizes these
aggregate production quotas at the same
amounts as proposed.
DEA also specifically considered that
inventory allowances granted to
individual manufacturers may not
always result in the availability of
sufficient quantities to maintain an
adequate reserve stock pursuant to 21
U.S.C. 826(a), as intended. See 21 CFR
1303.24. This would be concerning if a
natural disaster or other unforeseen
event resulted in substantial disruption
to the amount of controlled substances
available to provide for legitimate
public need. As such, the DEA included
in all Schedule II aggregate production
quotas, and certain Schedule I aggregate
production quotas, an additional 25% of
the estimated medical, scientific, and
research needs as part of the amount
necessary to ensure the establishment
and maintenance of reserve stocks. The
established aggregate production quotas
reflect these included amounts. This
action will not affect the ability of
manufacturers to maintain inventory
allowances as specified by regulation.
The DEA expects that maintaining this
reserve in certain established aggregate
production quotas will mitigate adverse
public effects if an unforeseen event
resulted in substantial disruption to the
amount of controlled substances
available to provide for legitimate
public need, as determined by the DEA.
The DEA does not anticipate utilizing
the reserve in the absence of these
circumstances.
In accordance with 21 U.S.C. 826, 21
CFR 1303.11, and 21 CFR 1315.11, the
Deputy Administrator hereby
establishes the 2014 aggregate
production quotas for the following
Schedule I and II controlled substances
and the 2014 assessment of annual
needs for the List I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
Established 2014
Quotas (grams)
tkelley on DSK3SPTVN1PROD with NOTICES
Basic Class—Schedule I
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) .............................................................................
[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ..................................................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ......................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) .....................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine .............................................................................................................................................
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) .........................................................................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073) ......................................................................................................................................
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) .....................................................................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019) .....................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine .....................................................................................................................................
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) ................................................................................................................
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) ......................................................................................................................
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ..................................................................................................................
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) ......................................................................................................................
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) .....................................................................................................................
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) ..............................................................................................................
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) .................................................................................................................
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) .............................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) .....................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ..................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ....................................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) .................................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ..................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ........................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine ...............................................................................................................................
2,5-Dimethoxyamphetamine ..........................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ..........................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) ....................................................................................................
3,4,5-Trimethoxyamphetamine ......................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ......................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) ...........................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .......................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ....................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) .....................................................................................................................................
3-Methylfentanyl .............................................................................................................................................................................
3-Methylthiofentanyl .......................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ............................................................................................................................
4-Methoxyamphetamine ................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................
4-Methylaminorex ..........................................................................................................................................................................
VerDate Mar<15>2010
15:01 Sep 06, 2013
Jkt 229001
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
E:\FR\FM\09SEN1.SGM
09SEN1
15
15
10
45
45
15
45
45
45
45
2
45
45
45
45
45
45
45
30
30
30
30
30
30
30
25
25
25
30
30
25
55
50
40
50
35
2
2
25
25
100
25
25
Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices
Established 2014
Quotas (grams)
tkelley on DSK3SPTVN1PROD with NOTICES
Basic Class—Schedule I
4-Methyl-N-methylcathinone (mephedrone) ..................................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ...................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47, 497 C8-homolog) ....................
5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine ...............................................................................................................................................
Acetyl-alpha-methylfentanyl ...........................................................................................................................................................
Acetyldihydrocodeine .....................................................................................................................................................................
Acetylmethadol ..............................................................................................................................................................................
Allylprodine ....................................................................................................................................................................................
Alphacetylmethadol ........................................................................................................................................................................
Alpha-ethyltryptamine ....................................................................................................................................................................
Alphameprodine .............................................................................................................................................................................
Alphamethadol ...............................................................................................................................................................................
Alpha-methylfentanyl .....................................................................................................................................................................
Alpha-methylthiofentanyl ................................................................................................................................................................
Alpha-methyltryptamine (AMT) ......................................................................................................................................................
Aminorex ........................................................................................................................................................................................
Benzylmorphine .............................................................................................................................................................................
Betacetylmethadol .........................................................................................................................................................................
Beta-hydroxy-3-methylfentanyl ......................................................................................................................................................
Beta-hydroxyfentanyl .....................................................................................................................................................................
Betameprodine ...............................................................................................................................................................................
Betaprodine ....................................................................................................................................................................................
Bufotenine ......................................................................................................................................................................................
Cathinone .......................................................................................................................................................................................
Codeine Methylbromide .................................................................................................................................................................
Codeine-N-oxide ............................................................................................................................................................................
Desomorphine ................................................................................................................................................................................
Diethyltryptamine ...........................................................................................................................................................................
Difenoxin ........................................................................................................................................................................................
Dihydromorphine ............................................................................................................................................................................
Dimethyltryptamine ........................................................................................................................................................................
Dipipanone .....................................................................................................................................................................................
Fenethylline ....................................................................................................................................................................................
Gamma-hydroxybutyric acid ..........................................................................................................................................................
Heroin ............................................................................................................................................................................................
Hydromorphinol ..............................................................................................................................................................................
Hydroxypethidine ...........................................................................................................................................................................
Ibogaine .........................................................................................................................................................................................
Lysergic acid diethylamide (LSD) ..................................................................................................................................................
Marihuana ......................................................................................................................................................................................
Mescaline .......................................................................................................................................................................................
Methaqualone ................................................................................................................................................................................
Methcathinone ...............................................................................................................................................................................
Methyldesorphine ...........................................................................................................................................................................
Methyldihydromorphine ..................................................................................................................................................................
Morphine Methylbromide ...............................................................................................................................................................
Morphine Methylsulfonate ..............................................................................................................................................................
Morphine-N-oxide ..........................................................................................................................................................................
N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ...................................................................................................
N-Benzylpiperazine ........................................................................................................................................................................
N,N-Dimethylamphetamine ............................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ..................................................................................................................................................
N-Ethylamphetamine .....................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................
Noracymethadol .............................................................................................................................................................................
Norlevorphanol ...............................................................................................................................................................................
Normethadone ...............................................................................................................................................................................
Normorphine ..................................................................................................................................................................................
Para-fluorofentanyl .........................................................................................................................................................................
Parahexyl .......................................................................................................................................................................................
Phenomorphan ..............................................................................................................................................................................
Pholcodine .....................................................................................................................................................................................
Properidine .....................................................................................................................................................................................
Psilocybin .......................................................................................................................................................................................
Psilocyn ..........................................................................................................................................................................................
Tetrahydrocannabinols ..................................................................................................................................................................
Thiofentanyl ...................................................................................................................................................................................
Tilidine ............................................................................................................................................................................................
Trimeperidine .................................................................................................................................................................................
VerDate Mar<15>2010
15:01 Sep 06, 2013
Jkt 229001
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
55101
E:\FR\FM\09SEN1.SGM
09SEN1
45
68
53
25
25
25
2
2
2
2
2
25
2
2
2
2
25
25
2
2
2
2
2
2
3
70
5
200
5
25
50
3,990,000
35
5
5
70,250,000
25
2
2
5
35
21,000
25
10
25
2
2
5
5
175
15
25
25
5
24
24
2
52
2
18
2
5
2
2
2
30
30
491,000
2
10
2
55102
Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices
Established 2014
Quotas (grams)
Basic Class—Schedule II
1-Phenylcyclohexylamine ..............................................................................................................................................................
1-Piperdinocyclohexanecarbonitrile (PCC) ....................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) ...................................................................................................................................
Alfentanil ........................................................................................................................................................................................
Alphaprodine ..................................................................................................................................................................................
Amobarbital ....................................................................................................................................................................................
Amphetamine (for conversion) ......................................................................................................................................................
Amphetamine (for sale) .................................................................................................................................................................
Carfentanil ......................................................................................................................................................................................
Cocaine ..........................................................................................................................................................................................
Codeine (for conversion) ...............................................................................................................................................................
Codeine (for sale) ..........................................................................................................................................................................
Dextropropoxyphene ......................................................................................................................................................................
Dihydrocodeine ..............................................................................................................................................................................
Diphenoxylate ................................................................................................................................................................................
Ecgonine ........................................................................................................................................................................................
Ethylmorphine ................................................................................................................................................................................
Fentanyl .........................................................................................................................................................................................
Glutethimide ...................................................................................................................................................................................
Hydrocodone (for sale) ..................................................................................................................................................................
Hydromorphone .............................................................................................................................................................................
Isomethadone ................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ..................................................................................................................................................
Levomethorphan ............................................................................................................................................................................
Levorphanol ...................................................................................................................................................................................
Lisdexamfetamine ..........................................................................................................................................................................
Meperidine .....................................................................................................................................................................................
Meperidine Intermediate-A ............................................................................................................................................................
Meperidine Intermediate-B ............................................................................................................................................................
Meperidine Intermediate-C ............................................................................................................................................................
Metazocine .....................................................................................................................................................................................
Methadone (for sale) .....................................................................................................................................................................
Methadone Intermediate ................................................................................................................................................................
Methamphetamine .........................................................................................................................................................................
3
3
2,687,500
17,625
3
9
18,375,000
49,000,000
19
240,000
68,750,000
46,125,000
19
100,750
750,000
144,000
3
2,108,750
3
99,625,000
6,750,000
5
4
195
2,000
23,750,000
6,250,000
6
11
6
19
31,875,000
38,875,000
2,811,375
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,500,000 grams for methamphetamine mostly
for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)]
Methylphenidate .............................................................................................................................................................................
Morphine (for conversion) ..............................................................................................................................................................
Morphine (for sale) ........................................................................................................................................................................
Nabilone .........................................................................................................................................................................................
Noroxymorphone (for conversion) .................................................................................................................................................
Noroxymorphone (for sale) ............................................................................................................................................................
Opium (powder) .............................................................................................................................................................................
Opium (tincture) .............................................................................................................................................................................
Oripavine ........................................................................................................................................................................................
Oxycodone (for conversion) ..........................................................................................................................................................
Oxycodone (for sale) .....................................................................................................................................................................
Oxymorphone (for conversion) ......................................................................................................................................................
Oxymorphone (for sale) .................................................................................................................................................................
Pentobarbital ..................................................................................................................................................................................
Phenazocine ..................................................................................................................................................................................
Phencyclidine .................................................................................................................................................................................
Phenmetrazine ...............................................................................................................................................................................
Phenylacetone ...............................................................................................................................................................................
Racemethorphan ...........................................................................................................................................................................
Remifentanil ...................................................................................................................................................................................
Secobarbital ...................................................................................................................................................................................
Sufentanil .......................................................................................................................................................................................
Tapentadol .....................................................................................................................................................................................
Thebaine ........................................................................................................................................................................................
Proposed 2014
Quotas
tkelley on DSK3SPTVN1PROD with NOTICES
Basic Class—List I Chemicals
Ephedrine (for conversion) ............................................................................................................................................................
Ephedrine (for sale) .......................................................................................................................................................................
Phenylpropanolamine (for conversion) ..........................................................................................................................................
Phenylpropanolamine (for sale) .....................................................................................................................................................
Pseudoephedrine (for conversion) ................................................................................................................................................
Pseudoephedrine (for sale) ...........................................................................................................................................................
VerDate Mar<15>2010
15:01 Sep 06, 2013
Jkt 229001
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
96,750,000
91,250,000
62,500,000
30,375
17,500,000
1,462,500
112,500
625,000
22,750,000
9,250,000
149,375,000
25,000,000
7,750,000
35,000,000
6
19
3
67,000,000
3
3,750
215,003
6,255
17,500,000
145,000,000
E:\FR\FM\09SEN1.SGM
09SEN1
1,000,000
3,000,000
44,800,000
5,300,000
5,000
192,000,000
Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices
The Deputy Administrator also
establishes aggregate production quotas
for all other Schedule I and II controlled
substances included in 21 CFR 1308.11
and 1308.12 at zero. Pursuant to 21 CFR
1303.13 and 21 CFR 1315.13, upon
consideration of the relevant factors, the
Deputy Administrator may adjust the
2014 aggregate production quotas and
assessment of annual needs as needed.
Dated: August 30, 2013.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2013–21797 Filed 9–6–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employee Benefits Security
Administration
[Application No. D–11758]
Notice of Proposed Exemption
involving AT&T Inc. (Together With
AT&T Inc.’s Affiliates, AT&T or the
Applicant) Located in Dallas, TX
Employee Benefits Security
Administration, U.S. Department of
Labor.
ACTION: Notice of Proposed Exemption.
AGENCY:
This document contains a
notice of pendency before the
Department of Labor (the Department) of
a proposed individual exemption from
certain prohibited transaction
restrictions of the Employee Retirement
Income Security Act of 1974, as
amended (ERISA or the Act), and the
Internal Revenue Code of 1986, as
amended (the Code). The proposed
transactions involve AT&T, the AT&T
Pension Benefit Plan (the Plan), and the
SBC Master Pension Trust (the Trust).
The proposed exemption, if granted,
would affect the Plan and its
participants and beneficiaries.
Effective Date: If granted, this
proposed exemption will be effective as
of September 1, 2013.
DATES: Written comments and requests
for a public hearing on the proposed
exemption should be submitted to the
Department within 55 days from the
date of publication of this Federal
Register Notice.
ADDRESSES: Comments and requests for
a hearing should state: (1) The name,
address, and telephone number of the
person making the comment or request,
and (2) the nature of the person’s
interest in the proposed exemption and
the manner in which the person would
be adversely affected by the exemption,
if granted. A request for a hearing must
also state the issues to be addressed and
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:01 Sep 06, 2013
Jkt 229001
include a general description of the
evidence to be presented at the hearing.
All written comments and requests for
a public hearing concerning the
proposed exemption should be sent to
the Office of Exemption Determinations,
Employee Benefits Security
Administration, Room N–5700, U.S.
Department of Labor, 200 Constitution
Avenue NW., Washington DC 20210,
Attention: Application No. D–11758.
Interested persons are also invited to
submit comments and/or hearing
requests to EBSA via email or FAX. Any
such comments or requests should be
sent either by email to: moffitt.betty@
dol.gov, or by FAX to (202) 219–0204 by
the end of the scheduled comment
period. The application for exemption
and the comments received will be
available for public inspection in the
Public Documents Room of the
Employee Benefits Security
Administration, U.S. Department of
Labor, Room N–1513, 200 Constitution
Avenue NW., Washington, DC 20210.
Comments and hearing requests will
also be available online at
www.regulations.gov and www.dol.gov/
ebsa, at no charge.
Warning: If you submit written
comments or hearing requests, do not
include any personally identifiable
information (such as name, address, or
other contact information) or
confidential business information that
you do not want publicly disclosed. All
comments and hearing requests may be
posted on the Internet and can be
retrieved by most Internet search
engines.
FOR FURTHER INFORMATION CONTACT:
Anna Mpras Vaughan, Office of
Exemption Determinations, Employee
Benefits Security Administration, U.S.
Department of Labor, telephone (202)
693–8565. (This is not a toll-free
number.)
SUPPLEMENTARY INFORMATION: This
document contains a notice of proposed
exemption that, if granted, would
provide exemptive relief from sections
406(a)(1)(A), 406(a)(1)(B), 406(a)(1)(D),
406(a)(1)(E), 406(a)(2), 406(b)(1),
406(b)(2), and 407(a) of the Act and the
sanctions resulting from the application
of section 4975 of the Code, by reason
of section 4975(c)(1)(A), 4975(c)(1)(B),
4975(c)(1)(D) and 4975(c)(1)(E) of the
Code. The proposed exemption has been
requested by AT&T pursuant to section
408(a) of the Act and section 4975(c)(2)
of the Code, and in accordance with the
procedures set forth in 29 CFR Part
2570, Subpart B (76 FR 66637, 66644,
October 27, 2011). Effective December
31, 1978, section 102 of the
Reorganization Plan No. 4 of 1978, 5
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
55103
U.S.C. App. 1 (1996), transferred the
authority of the Secretary of the
Treasury to issue administrative
exemptions under section 4975(c)(2) of
the Code to the Secretary of Labor.
Accordingly, this notice of proposed
exemption is being issued solely by the
Department.
Summary of Facts and
Representations 1
Background
1. AT&T Inc. (together with its
affiliates, AT&T), formerly known as
SBC Communications Inc., is a holding
company incorporated in 1983 under
the laws of the State of Delaware that
has its principal executive offices in
Dallas, Texas. AT&T, a provider of
telecommunications services, offers its
services and products to consumers in
the U.S. and to businesses and other
providers of telecommunications
services worldwide. The services and
products that AT&T offers vary by
market, and include: wireless
communications, local exchange
services, long-distance services, data/
broadband and Internet services, video
services, telecommunications
equipment, managed networking and
wholesale services.
2. AT&T is the sponsor of the AT&T
Pension Benefit Plan (the Plan).
Effective December 14, 2010, the Plan
was amended (the 2010 Amendment) to
name the Plan’s named fiduciary, AT&T
Services, as the plan administrator.
AT&T Services, pursuant to delegation
(the Delegation) from its Board of
Directors (the Board) dated July 1, 2011,
delegated to the AT&T Inc. Benefit Plan
Investment Committee (the Committee)
all powers and authority that may be
necessary or appropriate to the
establishment, qualification,
administration, maintenance, and
operation of the SBC Master Pension
Trust (the Trust) established as part of
the Plan. Notwithstanding its power to
delegate authority, the Committee
retains, and may not delegate, the
authority to authorize ‘‘companydirected’’ investments (i.e., investments
that have not been delegated to a third
party investment manager) in amounts
greater than $200,000,000.
3. In addition to AT&T Services and
the Committee, other Plan fiduciaries
include Brock Fiduciary Services LLC
(the Independent Fiduciary), an
investment manager that is independent
of AT&T Inc.
1 The Summary of Facts and Representations is
based on the Applicant’s representations and does
not reflect the views of the Department.
E:\FR\FM\09SEN1.SGM
09SEN1
]]>Agencies
[Federal Register Volume 78, Number 174 (Monday, September 9, 2013)]
[Notices]
[Pages 55099-55103]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-21797]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-378]
Established Aggregate Production Quotas for Schedule I and II
Controlled Substances and Established Assessment of Annual Needs for
the List I Chemicals Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2014
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice establishes the initial 2014 aggregate production
quotas for controlled substances in Schedules I and II of the
Controlled Substances Act (CSA) and assessment of annual needs for the
List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
DATES: Effective: September 9, 2013.
FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Chief, Policy
Evaluation and Analysis Section, Office of Diversion Control, Drug
Enforcement Administration, 8701 Morrissette Drive, Springfield, VA
22152, Telephone: (202) 598-6812.
SUPPLEMENTARY INFORMATION:
Background
Section 306 of the CSA (21 U.S.C. 826) requires the Attorney
General to establish aggregate production quotas for each basic class
of controlled substance listed in Schedules I and II and for the List I
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. This
responsibility has been delegated to the Administrator of the DEA by 28
CFR 0.100. The Administrator, in turn, has redelegated this function to
the Deputy Administrator, pursuant to 28 CFR 0.104.
The 2014 aggregate production quotas and assessment of annual needs
represent those quantities of Schedules I and II controlled substances
and the List I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine to be manufactured in the United States in 2014 to
provide for the estimated medical, scientific, research, and industrial
needs of the United States, lawful export requirements, and the
establishment and maintenance of reserve stocks. These quotas include
imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do
not include imports of controlled substances for use in industrial
processes.
On July 3, 2013, a notice titled, ``Proposed Aggregate Production
Quotas for Schedule I and II Controlled Substances and Proposed
Assessment of Annual Needs for the List I Chemicals Ephedrine,
Pseudoephedrine, and Phenylpropanolamine for 2014,'' was published in
the Federal Register (78 FR 40186). That notice proposed the 2014
aggregate production quotas for each basic class of controlled
substance listed in Schedules I and II and the 2014 assessment of
annual needs for the List I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. All interested persons were invited to comment on
or object to the proposed aggregate production quotas and the proposed
assessment of annual needs on or before August 2, 2013.
Comments Received
DEA received seven comments from DEA-registered manufacturers
within the published comment period on a total of 23 Schedule I and II
controlled substances and one List I chemical. Commenters stated that
the proposed aggregate production quotas for (1-Pentyl-1H-indol-3-
yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-
pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone
(XLR11), N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48),
cathinone, amphetamine (for sale), codeine (for conversion), codeine
(for sale), fentanyl, hydrocodone (for sale), hydromorphone,
levomethorphan, methylphenidate, morphine (for conversion), morphine
(for sale), noroxymorphone (for conversion), oripavine, oxycodone (for
sale), oxymorphone (for conversion), oxymorphone (for sale),
phenylacetone, tapentadol, tetrahydrocannabinol, and thebaine were
insufficient to provide for the estimated medical, scientific,
research, and industrial needs of the United States, export
requirements, and the establishment and maintenance of reserve stocks.
One commenter stated that the proposed assessment of annual needs quota
for phenylpropanolamine (for conversion) was insufficient to provide
for the estimated medical, scientific, research, and industrial needs
of the United States, export requirements, and the establishment and
maintenance of reserve stocks.
Determination of 2014 Aggregate Production Quotas and Assessment of
Annual Needs
In determining the 2014 aggregate production quotas and assessment
of annual needs, the DEA has taken into consideration the above
comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR
1315.11, in accordance with 21 U.S.C. 826(a), and other relevant
factors, including the consideration of 2013 manufacturing quotas,
current 2013 sales and inventories, 2014 export requirements,
industrial use, additional applications for quotas, as well as
information on research and product development requirements. Based on
this information, the DEA has determined that adjustments to the
proposed aggregate production quotas and assessment of annual needs for
1-[1-(2-Thienyl)cyclohexyl]piperidine, carfentanil, cathinone,
dihydromorphine, dimethyltryptamine, ecgonine, hydromorphone,
levomethorphan, lysergic acid diethylamide, metazocine,
methamphetamine, d-methamphetamine (for conversion), methyldesorphine,
noroxymorphone (for conversion), oxymorphone (for conversion),
phencyclidine, phenylacetone, ephedrine (for conversion), ephedrine
(for sale),
[[Page 55100]]
phenylpropanolamine (for conversion), and pseudoephedrine (for sale)
are warranted. This notice reflects those adjustments.
Regarding (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H-
indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11), N-(1-
adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48), amphetamine (for
sale), codeine (for conversion), codeine (for sale), fentanyl,
hydrocodone (for sale), methylphenidate, morphine (for conversion),
morphine (for sale), oripavine, oxycodone (for sale), oxymorphone (for
sale), tapentadol, tetrahydrocannabinol, thebaine, and
phenylpropanolamine (for sale), the DEA has determined that the
proposed initial 2014 aggregate production quotas and assessment of
annual needs are sufficient to meet the current 2014 estimated medical,
scientific, research, and industrial needs of the United States. This
notice finalizes these aggregate production quotas at the same amounts
as proposed.
DEA also specifically considered that inventory allowances granted
to individual manufacturers may not always result in the availability
of sufficient quantities to maintain an adequate reserve stock pursuant
to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be
concerning if a natural disaster or other unforeseen event resulted in
substantial disruption to the amount of controlled substances available
to provide for legitimate public need. As such, the DEA included in all
Schedule II aggregate production quotas, and certain Schedule I
aggregate production quotas, an additional 25% of the estimated
medical, scientific, and research needs as part of the amount necessary
to ensure the establishment and maintenance of reserve stocks. The
established aggregate production quotas reflect these included amounts.
This action will not affect the ability of manufacturers to maintain
inventory allowances as specified by regulation. The DEA expects that
maintaining this reserve in certain established aggregate production
quotas will mitigate adverse public effects if an unforeseen event
resulted in substantial disruption to the amount of controlled
substances available to provide for legitimate public need, as
determined by the DEA. The DEA does not anticipate utilizing the
reserve in the absence of these circumstances.
In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR
1315.11, the Deputy Administrator hereby establishes the 2014 aggregate
production quotas for the following Schedule I and II controlled
substances and the 2014 assessment of annual needs for the List I
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine,
expressed in grams of anhydrous acid or base, as follows:
------------------------------------------------------------------------
Established 2014
Basic Class--Schedule I Quotas (grams)
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3- 15
tetramethylcyclopropyl)methanone (UR-144)...........
[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 15
tetramethylcyclopropyl)methanone (XLR11)............
1-(1-Phenylcyclohexyl)pyrrolidine.................... 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201).... 45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)... 45
1-[1-(2-Thienyl)cyclohexyl]piperidine................ 15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH- 45
200)................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073).............. 45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR- 45
18 and RCS-8).......................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019).............. 45
1-Methyl-4-phenyl-4-propionoxypiperidine............. 2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)... 45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).... 45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)... 45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398).... 45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122).... 45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) 45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081).. 45
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)..... 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N).... 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)............. 30
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).... 30
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)...... 30
2,5-Dimethoxy-4-ethylamphetamine (DOET).............. 25
2,5-Dimethoxy-4-n-propylthiophenethylamine........... 25
2,5-Dimethoxyamphetamine............................. 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T- 30
2)..................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine 30
(2C-T-4)............................................
3,4,5-Trimethoxyamphetamine.......................... 25
3,4-Methylenedioxyamphetamine (MDA).................. 55
3,4-Methylenedioxymethamphetamine (MDMA)............. 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)......... 40
3,4-Methylenedioxy-N-methylcathinone (methylone)..... 50
3,4-Methylenedioxypyrovalerone (MDPV)................ 35
3-Methylfentanyl..................................... 2
3-Methylthiofentanyl................................. 2
4-Bromo-2,5-dimethoxyamphetamine (DOB)............... 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)........... 25
4-Methoxyamphetamine................................. 100
4-Methyl-2,5-dimethoxyamphetamine (DOM).............. 25
4-Methylaminorex..................................... 25
[[Page 55101]]
4-Methyl-N-methylcathinone (mephedrone).............. 45
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3- 68
hydroxycyclohexyl]-phenol...........................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 53
phenol (cannabicyclohexanol or CP-47, 497 C8-
homolog)............................................
5-Methoxy-3,4-methylenedioxyamphetamine.............. 25
5-Methoxy-N,N-diisopropyltryptamine.................. 25
5-Methoxy-N,N-dimethyltryptamine..................... 25
Acetyl-alpha-methylfentanyl.......................... 2
Acetyldihydrocodeine................................. 2
Acetylmethadol....................................... 2
Allylprodine......................................... 2
Alphacetylmethadol................................... 2
Alpha-ethyltryptamine................................ 25
Alphameprodine....................................... 2
Alphamethadol........................................ 2
Alpha-methylfentanyl................................. 2
Alpha-methylthiofentanyl............................. 2
Alpha-methyltryptamine (AMT)......................... 25
Aminorex............................................. 25
Benzylmorphine....................................... 2
Betacetylmethadol.................................... 2
Beta-hydroxy-3-methylfentanyl........................ 2
Beta-hydroxyfentanyl................................. 2
Betameprodine........................................ 2
Betaprodine.......................................... 2
Bufotenine........................................... 3
Cathinone............................................ 70
Codeine Methylbromide................................ 5
Codeine-N-oxide...................................... 200
Desomorphine......................................... 5
Diethyltryptamine.................................... 25
Difenoxin............................................ 50
Dihydromorphine...................................... 3,990,000
Dimethyltryptamine................................... 35
Dipipanone........................................... 5
Fenethylline......................................... 5
Gamma-hydroxybutyric acid............................ 70,250,000
Heroin............................................... 25
Hydromorphinol....................................... 2
Hydroxypethidine..................................... 2
Ibogaine............................................. 5
Lysergic acid diethylamide (LSD)..................... 35
Marihuana............................................ 21,000
Mescaline............................................ 25
Methaqualone......................................... 10
Methcathinone........................................ 25
Methyldesorphine..................................... 2
Methyldihydromorphine................................ 2
Morphine Methylbromide............................... 5
Morphine Methylsulfonate............................. 5
Morphine-N-oxide..................................... 175
N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide 15
(AKB48).............................................
N-Benzylpiperazine................................... 25
N,N-Dimethylamphetamine.............................. 25
N-Ethyl-1-phenylcyclohexylamine...................... 5
N-Ethylamphetamine................................... 24
N-Hydroxy-3,4-methylenedioxyamphetamine.............. 24
Noracymethadol....................................... 2
Norlevorphanol....................................... 52
Normethadone......................................... 2
Normorphine.......................................... 18
Para-fluorofentanyl.................................. 2
Parahexyl............................................ 5
Phenomorphan......................................... 2
Pholcodine........................................... 2
Properidine.......................................... 2
Psilocybin........................................... 30
Psilocyn............................................. 30
Tetrahydrocannabinols................................ 491,000
Thiofentanyl......................................... 2
Tilidine............................................. 10
Trimeperidine........................................ 2
------------------------------------------------------------------------
[[Page 55102]]
------------------------------------------------------------------------
Established 2014
Basic Class--Schedule II Quotas (grams)
------------------------------------------------------------------------
1-Phenylcyclohexylamine.............................. 3
1-Piperdinocyclohexanecarbonitrile (PCC)............. 3
4-Anilino-N-phenethyl-4-piperidine (ANPP)............ 2,687,500
Alfentanil........................................... 17,625
Alphaprodine......................................... 3
Amobarbital.......................................... 9
Amphetamine (for conversion)......................... 18,375,000
Amphetamine (for sale)............................... 49,000,000
Carfentanil.......................................... 19
Cocaine.............................................. 240,000
Codeine (for conversion)............................. 68,750,000
Codeine (for sale)................................... 46,125,000
Dextropropoxyphene................................... 19
Dihydrocodeine....................................... 100,750
Diphenoxylate........................................ 750,000
Ecgonine............................................. 144,000
Ethylmorphine........................................ 3
Fentanyl............................................. 2,108,750
Glutethimide......................................... 3
Hydrocodone (for sale)............................... 99,625,000
Hydromorphone........................................ 6,750,000
Isomethadone......................................... 5
Levo-alphacetylmethadol (LAAM)....................... 4
Levomethorphan....................................... 195
Levorphanol.......................................... 2,000
Lisdexamfetamine..................................... 23,750,000
Meperidine........................................... 6,250,000
Meperidine Intermediate-A............................ 6
Meperidine Intermediate-B............................ 11
Meperidine Intermediate-C............................ 6
Metazocine........................................... 19
Methadone (for sale)................................. 31,875,000
Methadone Intermediate............................... 38,875,000
Methamphetamine...................................... 2,811,375
------------------------------------------------------------------------
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
non-prescription product; 1,500,000 grams for methamphetamine mostly
for conversion to a schedule III product; and 61,375 grams for
methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate...................................... 96,750,000
Morphine (for conversion)............................ 91,250,000
Morphine (for sale).................................. 62,500,000
Nabilone............................................. 30,375
Noroxymorphone (for conversion)...................... 17,500,000
Noroxymorphone (for sale)............................ 1,462,500
Opium (powder)....................................... 112,500
Opium (tincture)..................................... 625,000
Oripavine............................................ 22,750,000
Oxycodone (for conversion)........................... 9,250,000
Oxycodone (for sale)................................. 149,375,000
Oxymorphone (for conversion)......................... 25,000,000
Oxymorphone (for sale)............................... 7,750,000
Pentobarbital........................................ 35,000,000
Phenazocine.......................................... 6
Phencyclidine........................................ 19
Phenmetrazine........................................ 3
Phenylacetone........................................ 67,000,000
Racemethorphan....................................... 3
Remifentanil......................................... 3,750
Secobarbital......................................... 215,003
Sufentanil........................................... 6,255
Tapentadol........................................... 17,500,000
Thebaine............................................. 145,000,000
------------------------------------------------------------------------
------------------------------------------------------------------------
Proposed 2014
Basic Class--List I Chemicals Quotas
------------------------------------------------------------------------
Ephedrine (for conversion)........................... 1,000,000
Ephedrine (for sale)................................. 3,000,000
Phenylpropanolamine (for conversion)................. 44,800,000
Phenylpropanolamine (for sale)....................... 5,300,000
Pseudoephedrine (for conversion)..................... 5,000
Pseudoephedrine (for sale)........................... 192,000,000
------------------------------------------------------------------------
[[Page 55103]]
The Deputy Administrator also establishes aggregate production
quotas for all other Schedule I and II controlled substances included
in 21 CFR 1308.11 and 1308.12 at zero. Pursuant to 21 CFR 1303.13 and
21 CFR 1315.13, upon consideration of the relevant factors, the Deputy
Administrator may adjust the 2014 aggregate production quotas and
assessment of annual needs as needed.
Dated: August 30, 2013.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2013-21797 Filed 9-6-13; 8:45 am]
BILLING CODE 4410-09-P
